Navigation Links
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
Date:1/28/2011

may significantly decrease pulmonary ventilation.  NUCYNTA® should be administered with caution to the elderly, debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma.  In such patients, even usual therapeutic doses of NUCYNTA® may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA® should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.  

Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma or death may result if these drugs are taken in combination with NUCYNTA®. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.

Opioid analgesics can raise cerebrospinal fluid pressure as a result of respiratory depression with carbon dioxide retention.  Therefore, NUCYNTA® should not be used in patients susceptible to the effects of raised cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure.  Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness.  NUCYNTA® should be used with caution in patients with head injury, intracranial lesions, or other sources of preexi
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
3. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
4. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
6. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
7. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
8. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
9. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
10. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
11. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... JOLLA, Calif. , Nov. 26, 2014   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and CEO of Regulus, ... Annual Piper Jaffray Healthcare Conference at the New ... 2:00 p.m. EST.  The presentation will be webcast at ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... ... of Body Mass Index -, PHILADELPHIA, Oct. 16 ... been,established, but healthcare professionals have had little guidance as to,whether ... with GERD. Two studies about obesity and its,relationship to GERD ...
... to File Supplemental New Drug Application with FDA in First ... ... FRANCISCO, Calif., Oct. 16 Anesiva,Inc. (Nasdaq: ANSV ) today ... randomized, double-blind study,with 699 adult patients met its primary endpoint, demonstrating ...
Cached Medicine Technology:Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 2Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 3Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 4Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 5Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 2Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 3Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 4Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 5
(Date:11/27/2014)... 28, 2014 One of the ... The market for implant dentistry comprises dental implants ... global market for dental care is bifurcated into ... dental equipment segment is composed of large equipment. ... at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection ... media player promotion for Dec. 2014. , The CEO ... in April, and this promotion will help to expand our ... models on our website, she/he can contact us with special ... models come in the latest designs, and they actually are ...
(Date:11/27/2014)... Turks and Caicos Islands; BWI (PRWEB) November 28, 2014 ... for the Tuscany Resort in the Turks & Caicos. ... resorts by TripAdvisor in Providenciales, is announcing a few ... three bedroom villa rentals. And they are offering ... resort. , Additionally, The Tuscany, is having a ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading ... in place to counter this. However, it doesn’t seem ... with menstrual blood are taken as seriously. , ... way to handle tampons and menstrual pads while also ... , He then created a prototype of the Sani-M, ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... PHILADELPHIA A research team led by Nancy Speck, ... Perelman School of Medicine at the University of Pennsylvania, ... of hematopoietic (blood) stem cells (HSCs) in the developing ... from engineered precursors., Because HSCs, found in the bone ...
... FOR DEC. 9, 2011] The investigation of a 2009 ... (STEC), an important cause of bacterial gastrointestinal illness, led ... Published in Clinical Infectious Diseases and ... offers recommendations for prevention, including a stronger message for ...
... ANTONIO -- Precisely quantifying the amount of three different ... linked to breast cancer , did not predict ... Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive ... human epidermal growth factor receptor 2 that promotes cancer ...
... quarter century of work in Malawi, a Michigan State ... MRI scans on children newly diagnosed with cerebral malaria ... Michael Potchen, an associate professor in the Department ... from the Dana Foundation, a private philanthropic organization supporting ...
... may help personalize pain medication management for sickle cell ... Dr. Cheedy Jaja, a nurse research scientist and ... National Institutes of Health grant to determine if variations ... opioids could help physicians manage sickle cell pain. ...
... blood test with other factors including the size of the ... up to one-quarter of men avoid biopsies and the risks ... team says. Writing in a study published online by ... G. Sanda, MD, Director of the Prostate Center at Beth ...
Cached Medicine News:Health News:Penn study unlocks origins of blood stem cells 2Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer 2Health News:Uncovering how cerebral malaria damages the brain 2Health News:Study probes genetic link to sickle cell pain management 2Health News:Study probes genetic link to sickle cell pain management 3Health News:Study probes genetic link to sickle cell pain management 4Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 2Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: